TRAJAN GROUP HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.01 AUD | -1.94% |
|
-10.22% | -18.22% |
| 27/02 | Trajan Group Swings to Loss in Fiscal H1, Revises Guidance; Shares Down 17% | MT |
| 26/02 | Transcript : Trajan Group Holdings Limited, H1 2024 Earnings Call, Feb 27, 2024 |
| Sales 2024 * | 162M 106M 8.83B | Sales 2025 * | 175M 115M 9.54B | Capitalization | 154M 101M 8.39B |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 1.97M 164M | Net income 2025 * | 7M 4.59M 382M | EV / Sales 2024 * | 1.21 x |
| Net Debt 2024 * | 41.2M 27.01M 2.25B | Net Debt 2025 * | 33.12M 21.71M 1.81B | EV / Sales 2025 * | 1.07 x |
| P/E ratio 2024 * |
33.6
x | P/E ratio 2025 * |
15.9
x | Employees | 600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Trajan Group Holdings Limited
| 1 day | -1.94% | ||
| 1 week | -10.22% | ||
| Current month | -6.05% | ||
| 1 month | -9.82% | ||
| 3 months | -9.01% | ||
| 6 months | -23.77% | ||
| Current year | -18.22% |
1 week
1.00
1.13
1 month
1.001.30
Current year
0.981.33
1 year
0.981.91
3 years
0.984.59
5 years
0.984.59
10 years
0.984.59
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Tomisich
FOU | Founder | - | 11/11/11 |
Alister Hodges
DFI | Director of Finance/CFO | - | 01/11/01 |
Nigel Gilligan
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Eales
CHM | Chairman | 54 | 01/21/01 |
Sara Watts
BRD | Director/Board Member | - | - |
Tiffiny Lewin
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 1.01 | -1.94% | 43 083 |
| 01/24/01 | 1.03 | -3.74% | 4,213 |
| 30/24/30 | 1.07 | +1.90% | 58,458 |
| 29/24/29 | 1.05 | -1.87% | 50,877 |
| 26/24/26 | 1.07 | -2.28% | 26,299 |
Delayed Quote Australian S.E., May 02, 2024 at 11:40 am IST
More quotes
Trajan Group Holdings Limited is an Australia-based developer and manufacturer of analytical and life sciences products and devices. The portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Company operates through two segments: Analytical Products and Life Science Solutions. The Analytical Products segment is involved in the designing, manufacturing, distribution and selling of analytical components and consumables. Life Science Solutions segment is involved in the designing, manufacturing, distribution and selling of pathology, automation workflow solutions, micro sampling devices, testing and data analysis. Its solutions include analytical, analytical services, sampling, pathology, and automation. Its pathology products include ZERO Exposure NBF containers, Series 1 Adhesive Microscope Slides, Series 1 Frosted Microscope Slides, and Series 2 Adhesive Microscope Slides.
Sector
Office Equipment
Calendar
21/08/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.01
AUD
Average target price
1.8
AUD
Spread / Average Target
+78.22%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.22% | 102M | |
| +9.51% | 8.03B | |
| -8.77% | 2.82B | |
| +5.40% | 2.1B | |
| -25.84% | 1.13B | |
| -10.46% | 828M | |
| -22.21% | 764M | |
| -14.18% | 745M | |
| -56.76% | 684M | |
| -23.48% | 682M |
- Stock Market
- Equities
- TRJ Stock
